Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK

Core Viewpoint - A class action has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have resulted in financial losses for shareholders [2]. Group 1: Allegations and Legal Action - The class action is on behalf of individuals and entities that purchased Cytokinetics securities between December 27, 2023, and May 6, 2025 [1]. - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission and approval process for aficamten, specifically regarding the expected approval timeline from the U.S. Food and Drug Administration (FDA) [2]. - Defendants claimed that approval was expected in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [2]. Group 2: Participation and Representation - Shareholders interested in serving as lead plaintiffs must submit their papers by November 17, 2025, to represent other class members in the litigation [3]. - Shareholders can choose not to participate in the case and still remain eligible for recovery as absent class members [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].